Clinical outcomes in elderly patients with metastatic colorectal cancer receiving bevacizumab and chemotherapy: Results from the BRiTE observational cohort study

Oncology

Volumn 78, Issue 5-6, 2010, Pages 329-339

  Kozloff, Mark F ^a   Berlin, Jordan ^b   Flynn, Patrick J ^c   Kabbinavar, Fairooz ^d   Ashby, Mark ^e   Dong, Wei ^e   Sing, Amy P ^e   Grothey, Axel ^f  

^a Ingalls Memorial Hospital   (United States)

^b VANDERBILT INGRAM CANCER CENTER   (United States)

^c Metro Minnesota CCOP   (United States)

^d UNIVERSITY OF CALIFORNIA   (United States)

^e GENENTECH INC   (United States)

^f MAYO CLINIC   (United States)

Author keywords

Bevacizumab; Chemotherapy; Metastatic colorectal cancer

Indexed keywords

BEVACIZUMAB; CAPECITABINE; FLUOROURACIL; FOLINIC ACID; IRINOTECAN; OXALIPLATIN; ALKALINE PHOSPHATASE; ANGIOGENESIS INHIBITOR; MONOCLONAL ANTIBODY;

ADULT; AGED; ARTERY DISEASE; ARTICLE; CANCER GROWTH; CANCER SURVIVAL; COLORECTAL CANCER; DRUG SAFETY; FEMALE; GROUPS BY AGE; HUMAN; MAJOR CLINICAL STUDY; MALE; METASTASIS; PRIORITY JOURNAL; PROGNOSIS; UNSPECIFIED SIDE EFFECT; BLOOD; CHEMICALLY INDUCED; COHORT ANALYSIS; COLORECTAL NEOPLASMS; COMPLICATION; DIABETES MELLITUS; DISEASE FREE SURVIVAL; FOLLOW UP; HYPERTENSION; MIDDLE AGED; MORTALITY; PATHOLOGY; PROPORTIONAL HAZARDS MODEL; SURVIVAL; THROMBOEMBOLISM; TIME; TREATMENT OUTCOME; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; ALKALINE PHOSPHATASE; ANGIOGENESIS INHIBITORS; ANTIBODIES, MONOCLONAL; COHORT STUDIES; COLORECTAL NEOPLASMS; DIABETES COMPLICATIONS; DISEASE-FREE SURVIVAL; FEMALE; FOLLOW-UP STUDIES; HUMANS; HYPERTENSION; MALE; MIDDLE AGED; NEOPLASM METASTASIS; PROPORTIONAL HAZARDS MODELS; SURVIVAL ANALYSIS; THROMBOEMBOLISM; TIME FACTORS; TREATMENT OUTCOME; ANTIBODIES, MONOCLONAL, HUMANIZED;

EID: 77956072936     PISSN: 00302414     EISSN: None     Source Type: Journal    
DOI: 10.1159/000320222     Document Type: Article

References (20)

1. National Cancer Institute: SEER Cancer Statistics Review 1975-2005. http://seer.cancer. gov/csr/1975- 2005/result s-merged/ sect-06-colon-rectum.pdf (accessed July 20, 2008).
2. Taylor M, Chu L, Sugrue M, Dong W: Median survival in newly diagnosed metastatic colorectal cancer patients and its variability by age and comorbidity. Am Soc Clin Oncol Gastrointest Cancers Symp, Orlando, 2008, abstr 397.
3. Hutchins LF, Unger JM, Crowley JJ, Coltman CA Jr, Albain KS: Underrepresentation of patients 65 years of age or older in cancertreatment trials. N Engl J Med 1999; 341: 2061-2067.
4. Lewis JH, Kilgore ML, Goldman DP, et al: Participation of patients 65 years of age or older in cancer clinical trials. J Clin Oncol 2003; 21: 1383-1389.
5. Talarico L, Chen G, Pazdur R: Enrollment of elderly patients in clinical trials for cancer drug registration: a 7-year experience by the US Food and Drug Administration. J Clin Oncol 2004; 22: 4626-4631.
6. Trimble EL, Christian MC: Cancer treatment and the older patient. Clin Cancer Res 2006; 12: 1956-1957.
7. Kabbinavar F, Hurwitz HI, Fehrenbacher L, et al: Phase II, randomized trial comparing bevacizumab plus fluorouracil (FU)/leucovorin (LV) with FU/LV alone in patients with metastatic colorectal cancer. J Clin Oncol 2003; 21: 60-65.
8. Hurwitz H, Fehrenbacher L, Novotny W, et al: Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 2004; 350: 2335-2342.
9. Giantonio BJ, Catalano PJ, Meropol NJ, et al: Bevacizumab in combination with oxaliplatin, fluorouracil, and leucovorin (FOLFOX4) for previously treated metastatic colorectal cancer: results from the Eastern Cooperative Oncology Group study E3200. J Clin Oncol 2007; 25: 1539-1544.
10. US Census Bureau: US interim projections by age, sex, race, and Hispanic origin. 2004. http://www.census.gov/ipc/www/usinterimproj/ natprojtab02a.pdf.
11. Ferrara N, Gerber HP: The role of vascular endothelial growth factor in angiogenesis. Acta Haematol 2001;106:148-156.
12. Kabbinavar FF, Hurwitz, HI, Yi J, et al: Addition of bevacizumab to fluorouracil-based first-line treatment of metastatic colorectal cancer: pooled analysis of cohorts of older patients from two randomized clinical trials. J Clin Oncol 2009; 27: 199-205.
13. Cassidy J, Saltz LB, Gianantonio BJ, et al: Effect of bevacizumab in older patients with metastatic colorectal cancer: pooled analysis of four randomized studies. J Cancer Res Clin Oncol 2010; 136: 737-743.
14. Kozloff M, Yood M, Berlin J, et al: Clinical outcomes associated with bevacizumabcontaining treatment of metastatic colorectal cancer: the BRiTE Observational Cohort Study. Oncologist 2009; 14: 862-870.
15. World Health Organization: Definition of an older or elderly person. 2010. http://www. who.int/healthinfo/survey/ageingdefnolder/ en/index.html
16. Zhang X, Loberiza FR, Klein JP, Zhang MJ: A SAS macro for estimation of direct adjusted survival curves based on a stratified Cox regression model. Comput Methods Programs Biomed 2007; 88: 95-101.
17. Gillison TL, Chatta GS: Cancer chemotherapy in the elderly patient. Oncology 2010; 24: 76-85.
18. Kabbinavar FF, Schulz J, McCleod M, et al: Addition of bevacizumab to bolus fluorouracil and leucovorin in first-line metastatic colorectal cancer: results of a randomized phase II trial. J Clin Oncol 2005; 23: 3697-3705.
19. Scappaticci FA, Skillings JR, Holden SN, et al: Arterial thromboembolic events in patients with metastatic carcinoma treated with chemotherapy and bevacizumab. J Natl Cancer Inst 2007; 99: 1232-1239.
20. Grothey A, Sugrue MM, Purdie DM, et al: Bevacizumab beyond first progression is associated with prolonged overall survival in metastatic colorectal cancer: results from a large observational cohort study (BRiTE). J Clin Oncol 2008; 33: 5326-5334.